The restriction of TTBK1 expression to the CNS and its ability to phosphorylate tau at S422, a phosphorylation site previously shown to be increased in a variety of neurodegenerative diseases, makes TTBK1 an exciting target for the treatment of tauopathies. Here, MAPT is linked to neurodegenerative disease.